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While various modalities to determine risk of sudden cardiac death (SCD) have been re-
ported in clinical studies, currently reduced left ventricular ejection fraction remains the
cornerstone of SCD risk stratification. However, the absolute burden of SCD is greatest
amongst populations without known cardiac disease. In this review, we summarize the
evidence behind current guidelines for implantable cardioverter defibrillator (ICD) use for
the prevention of SCD in patients with ischemic heart disease (IHD). We also evaluate the
evidence for risk stratification tools beyond clinical guidelines in the general population,
patients with IHD, and patients with other known or suspected medical conditions.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
In spite of the advances in modern technology, accurate
identification of the patient who will experience sudden car-
diac death (SCD) remains one of the holy grails of cardiology.
The closest the clinician can come to prediction is an estima-
tion of risk for this event which is likely to be terminal, and to
determine an approximate categorization of patients into high
and low risk groups. Appropriate high risk patients can be
offered an implantable cardioverter defibrillator (ICD), the only
currently available option for SCD prevention. However, the
ICD is incompletely effective in preventing SCD since it treats
only ventricular tachyarrhythmias but not electromechanical
dissociation/pulseless electrical activity in the failing heart., Philadelphia, PA 19107, U
du (Behzad B. Pavri).
2013, Cardiological SocietThe overall annual incidence of SCD, based on extrapola-
tion of data from the United States, is approximately 1 in 1000
adults over the age of 35 years.1 While SCD occurs in a higher
proportion of adults with traditional cardiac risk factors and a
history of heart disease, the absolute number of SCDs which
occur in the general population by far outnumber the absolute
number of SCDs in the high risk groups. Thus the majority of
SCD accrues from the general population, in whom there are
no currently available screening tools.
Prevention of SCD can be categorized into primary pre-
vention (i.e., in patients with no prior history of SCD), and
secondary prevention (i.e., in patients with a history of
resuscitated cardiac arrest, unstable ventricular tachycardia
(VT), ventricular fibrillation (VF), or syncope with high risk
features). The focus of this review will be primary preventionSA. Tel.: þ1 215 955 5050; fax: þ1 215 955 9710.
y of India. All rights reserved.
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be discussed briefly for completeness.
We present here an enumeration and summary of pro-
spective clinical studies evaluating SCD risk in three cate-
gories of patients: the population of patients with ischemic
heart disease (IHD), populations of patients with other high-
risk conditions, both cardiac and non-cardiac, and the gen-
eral population. Only studies with a sample size of at least 200
patients were included in this review. The tools available for
risk stratification of SCD can be broadly categorized as fol-
lows: historical factors, autonomic parameters, biomarkers,
characteristics of the surface ECG, invasive electrophysio-
logical study (EPS), left ventricular ejection fraction (LVEF),
and assessment of myocardial scar burden. Populations with
congenital disorders known to carry a high risk of SCD,
namely long QT syndrome, short QT syndrome, Brugada
syndrome, hypertrophic cardiomyopathy, arrhythmogenic
right ventricular cardiomyopathy, tetratogy of Fallot,
WolffeParkinsoneWhite syndrome, and idiopathic VT are
excluded from this review, and addressed elsewhere in this
supplement.2. Primary prevention of SCD in patients
with ischemic heart disease (IHD)
2.1. Left ventricular ejection fraction (LVEF)
The mainstay of current clinical guidelines in the determi-
nation of patients at high risk for SCD is the LVEF. LVEF has
been recognized as a predictor of overall cardiac mortality in
IHD patients since the 1980’s.2 For this reason, clinical trials
evaluating the efficacy of the ICDs in primary prevention of
SCD have consistently used LVEF cut-offs in the selection of
patients. Large clinical trials on SCD risk stratification over the
last 20 years have all proven a reduction in SCD with ICD use
in patients with reduced LVEF.Fig. 1 e Current recommendations for appropriate use of impla
patients. Numbers indicate new evidence shown in Table 1 for
patients. LVEF e left ventricular ejection fraction, MI e myocard
tachycardia, VT e ventricular tachycardia, EPS e electrophysiol
CABG e coronary artery bypass graft, GDMT e goal-directed meIn 1999, the Multicenter Unsustained Tachycardia Trial
(MUSTT), showed that amongst 704 coronary artery disease
patients with LVEF 40% asymptomatic non-sustained ven-
tricular tachycardia (NSVT), and inducible sustained ventric-
ular tachyarrhythmias on EPS, ICD therapy decreased the risk
of SCD by 27% over a 2 year follow up period. In comparison,
anti-arrhythmic drug therapywas not found to be beneficial in
reducing the risk of SCD. Patients who were inducible to
sustained VT (whether treated with anti-arrhythmic drugs or
not) fared worse than non-inducible patients, highlighting the
ability of EPS to stratify risk.3 In 2002, the Multicenter Auto-
matic Defibrillator Implantation Trial (MADIT II) showed that
amongst 1232 patients following myocardial infarction (MI)
with LVEF30%, prophylactic ICD implantation decreased the
rate of SCD by over 30% over a follow up period of 20 months.4
In 2005, the Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT), showed that amongst 2521 NewYorkHeart Association
(NYHA) class II or III heart failure patients (due to both
ischemic and non-ischemic causes) with LVEF 35%, ICD
implantation reduced overall mortality by 23% over a median
follow up period of 45.5 months.5
Clinical trials directly evaluating the risk of SCD among
various LVEF strata are comparatively fewer. In 2008, the
Improved Stratification of Autonomic Regulation (ISAR-risk)
study showed that amongst 2343 survivors of MI in sinus
rhythm, LVEF 30% predicted increased all cause mortality
and SCD compared with LVEF >30%.6 The Risk Estimation
Following Infarction, Noninvasive Evaluation (REFINE) trial in
2007 showed that amongst 322 post-MI patients, LVEF30% as
compared with LVEF >30% had an increased risk of SCD or
resuscitated cardiac arrest (HR 3.30, p¼ 0.005).7 This paucity of
trials directly comparing SCD risk in different LVEF strata
contributes to the discordance of LVEF cut-offs across various
published clinical guidelines for primary prevention ICD im-
plantation.8 The most recent 2013 consensus guidelines on
appropriate use of ICD for the primary prevention of SCD in
IHD are summarized in Fig. 1.9 In these latest guidelines, LVEFntable cardioverter defibrillators in ischemic heart disease
additional risk stratification tools in the given subsets of
ial infarction, NSVT e non-sustained ventricular
ogy study, PCI e percutaneous coronary intervention,
dical therapy, NYHA e New York Heart Association.
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of a recent MI is the second step.
2.1.1. Timing of ICD implantation following MI
The only current recommendations for ICD use in patients
less than 40 days following MI comes from the previously
described 1999MUSTT trial, which included patients 4 ormore
days after MI. For this reason, current recommendations state
that ICD use is appropriate in patients 4e40 days after MI with
inducible VT on EPS.9 However, it should be noted that only 34
of 704 patients in the MUSTT trial were within 1 month of
myocardial infarction.
Apart from the above case, ICD use is not recommended in
patients less than 40 days following MI. The evidence for this
comes from the Defibrillator in Acute Myocardial Infarction
Trial (DINAMIT) and the Immediate Risk Stratification Im-
proves Survival (IRIS) trial. In 2004 the DINAMIT trial showed
that during 6e40 days following an MI in patients with LVEF
35% and impaired heart rate variability, ICD implantation
caused a decrease in the rate of death due to arrhythmia, but
that benefit was offset by an increase in the rate of non-
arrhythmic deaths.10 In 2009, the IRIS trial enrolled patients
5e31 days following MI with LVEF <¼40%, and either heart
rate of 90 or more on first available ECG or NSVT on Holter
monitoring. Patients were randomized to receive ICD or
medical therapy alone. ICD use was found not to reduce
overall mortality in these patients.11
2.2. Non-LVEF parameters for assessment of SCD risk
In addition to the studies for SCD risk stratification which
have been incorporated into the official guidelines, there is an
accumulating body of literature for various other tools in SCD
risk stratification amongst IHD patients (Table 1), but these
strategies have yet to be universally recommended or incor-
porated into guidelines. Data from the Duke Databank for
Cardiovascular disease, which included patients undergoing
cardiac catheterization at Duke University Medical Center and
found to have at least one native coronary artery stenosis of
75%, have identified various factors from a patient’s history
which increase the risk of SCD. While each of these factors
was independently predictive of SCD at a level which reached
statistical significance, hazard ratios obtained were relatively
low. These historical factors, LVEF, and the number of
diseased coronary arteries were combined by the authors to
develop the Duke SCD risk score which provides a numerical
estimation of risk over a 1e10 year follow up period. In this
model, LVEF still carried the greatest statistical importance
compared to all other variables. This model was internally
validated using a bootstrapping technique, and externally
validated in the SCD-HeFT database. The major limitation to
use of this clinical risk score is that even in the highest
quartile of this risk score, deaths due to SCD represent only 1
in 8 deaths that occur in this population, and the number
needed to treat with an ICD to prevent one SCD was 18 in the
highest risk quartile.12 Nevertheless, the Duke SCD risk score
remains a promising tool for SCD risk stratification beyond
current primarily LVEF-based guidelines.
Various parameters from the surface ECG have increas-
ingly been proven to reach levels of statistical significance inpredicting SCD. A Chinese study and an analysis of the
MADIT II study data in 2012 showed an increased risk of SCD
when QRS fragmentation was present in the inferior
leads.13,14 The Alternans Before Cardioverter Defibrillator
(ABCD) trial showed in 2010 that amongst patients with
LVEF 40% and NSVT who were more than 28 days post MI,
microvolt T wave alternans (MTWA) and EPS were indepen-
dent predictors of SCD; MTWA predicted events better in
patients with LVEF <30%, and EPS predicted events better in
patients with LVEF >30%. The use of EPS in patients with
LVEF 36e40% is already incorporated into clinical guidelines;
however the ABCD study suggests that the use of MTWA in
combination with EPS may better predict SCD risk, as each
may identify different arrhythmogenic substrates.15 It
should be noted that MTWA may have limited prognostic
ability in guiding patients who will benefit most from ICD
implantation; in CAD and reduced LVEF, MTWA results did
not predict higher risk of ventricular tachyarrhythmias and
ICD therapies.16
In 2010, the Metabolic Efficiency with Ranolazine for Less
Ischemia in Non-ST-elevation 36 (MERLIN-TIMI 36) trial eval-
uated 6345 patients within 48 h after hospitalization for non-
ST-elevation MI (NSTEMI) with 7 day outpatient ECG moni-
toring, with median follow up of 348 days. In this study,
increasing number of beats of spontaneous ventricular tachy-
cardia, and the presence of ischemia on continuous ECG moni-
toring was associated with an increased risk of SCD. An
increased QTc intervalwas also associated with increased SCD
risk.17e19 This study supports the use of continuous ECG
monitoring for 7 days followingNSTEMI to evaluate patients at
increased risk for SCD, a tool which is not currently in wide-
spread use.
Recent studies have evaluated novel echocardiographic
parameters of mechanical dispersion and strain echocardi-
ography in the use of risk stratification in patients who are
post MI, as they may reflect myocardial deformation hetero-
geneity. Both global longitudinal strain and increased me-
chanical dispersion have been shown to have a statistically
significant predictor of SCD risk.20,21
While most studies of SCD risk assessment involve a
baseline assessment of a certain clinical tool, and follow up at
one time point, the Valsartan in Acute Myocardial Infarction
trial (VALIANT), published in 2010, evaluated the time
dependence of risk factors. They found that in the immediate
hospitalization after MI, higher baseline heart rate and
impaired creatinine clearancewere the strongest predictors of
SCD among the variables that they evaluated. During long
term follow up of up to 3 years, the strongest predictors of SCD
were found to be prior MI, initial LVEF <40%, and recurrent
cardiovascular events; however the predictive power dimin-
ished with time. The authors argue that this implies that risk
stratification for SCD ought to be a dynamic and on-going
process.22 This study, however, did not reassess clinical pa-
rameters at each time point of follow up and rather based
their analysis on baseline values. The clinical implications of
this studymay be that in those forwhom the short term risk of
SCD based on risk stratification from baseline parameters is
low, ICD therapy may be delayed to avoid ICD related com-
plications for the time period for which they are considered
low risk.
Table 1 e Sudden cardiac death risk stratification tools in ischemic heart disease patients beyond current guidelines which have been evaluated in prospective clinical
studies, with the endpoint being either sudden cardiac death alone, or a composite of sudden cardiac death and ventricular tachycardia/fibrillation. See Fig. 1 for
correlation of where these tools may be incorporated into current guidelines.
Ref # Study name (location) Population (sample size) Risk stratification tool Hazard ratio or relative
risk for endpoint (95% CI)
p Value
14 1 (China) ICM LVEF<50%, GDMT, NYHA IIeIV (n ¼ 1054) b1 receptor auto-antibodies 3.749 (2.389e5.884) <0.001
fQRS in inferior leads 2.714 (1.809e4.072) <0.001
12 2 Duke Databank for
CVD (U.S.A.)
Patients with 1 native coronary artery
with 75% stenosis (n ¼ 37258)
History of diabetes 1.40 (1.25e1.56) <0.0001
History of hypertension 1.37 (1.24e1.53) <0.0001
History of HF 1.39 (1.23e1.58) <0.0001
History of cerebrovascular disease 1.49 (1.28e1.73) <0.0001
History of tobacco use 1.20 (1.08e1.34) 0.0008
LVEF (per 1% decrease) 1.05 (1.04e1.05) <0.0001
Diseased coronary arteries (per # increase) 1.37 (1.29e1.45) <0.0001
22 3 VALIANT (24 countries) Acute MI with HF or LVEF 40% (n ¼ 11256) HR per 10 beats/min increase: at initial
hospitalization, 6 months to 3 years later
1.20 (1.06e1.37),
1.10 (1.01e1.19)
NA, NA
CrCl per 10 cc/min: initial hospitalization,
discharge to 30 days
0.82 (0.74e0.91),
0.93 (0.87e0.99)
NA, NA
LVEF per 10% increase below 40%: initial
hospitalization, 6 months to 3 years later
0.74 (0.56e0.98),
0.67 (0.58e0.78)
NA, NA
AF post MI: initial hospitalization, 6 months
to 3 years later
2.03 (1.30e3.16),
1.65 (1.23e2.19)
NA, NA
Re-hospitalization: discharge to 30d, 6 months
to 3 years later
2.48 (1.52e4.06),
1.47 (1.17e1.86)
NA, NA
Interval HF: discharge to 30d, 6 months to
3 years later
2.19 (1.34e3.59),
1.45 (1.05e1.99)
NA, NA
15 3 ABCD (U.S.A, Germany,
Israel)
Age 18, ICM, NSVT, LVEF 40% (n ¼ 566) MTWA in LVEF 40% 2.7% vs. 0%a 0.04
MTWA in LVEF 30% 8.8% vs. 2.9%a <0.05
42 4 (USA) ICM EF 35%, no prior VA (n ¼ 768) MTWA 2.29 (1.00e5.24) 0.049
20 5 (Denmark) Acute MI (n ¼ 988) Global longitudinal strain on echo 1.24 (1.10e1.40) 0.0004
Mechanical dispersion by echo (per 10 ms increase) 1.15 (1.01e1.31) 0.032
19 6 MERLIN-TIMI 36 trial (U.S.A.,
Czech republic,
Netherlands)
NSTEMI 48 h prior (n ¼ 6345) 4e7 beats VT on 7 days of telemetry 2.3 (1.5e3.7) <0.001
19 8 beats of VT on 7 days of telemetry 2.8 (1.5e5.1) 0.001
17 VT 4 beats, 1 mm ST depression for 1 min 6.5 <0.001
18 QTc interval (450 ms in men, 470 ms in women) 2.3 0.005
21 7 (Norway, Belgium) >40d post MI (n ¼ 569) Mechanical dispersion by echo (per 10 ms increase) 1.7 (1.2e2.5) <0.01
43 8 MADIT II (U.S.A) Age 21, Prior MI (>1 month ago),
revascularization >3 months ago,
LVEF 30% (n ¼ 1232)
BMI (per 5 unit decrease) 1.41 (1.09e1.83) 0.01
44 SBP (per 10 mmHg increase) 0.84 (0.71e0.99) 0.04
45 Renal insufficiency 2.00 (1.01e4.02) 0.04
13 Inferior QRS fragmentation 2.05 0.007
13 Inferior QRS fragmentation in LBBB 4.24 0.002
46 Medically treated arm QRS duration >140 ms 2.12 (1.20e3.76) 0.01
CI e confidence interval, ICM e ischemic cardiomyopathy, LVEF e left ventricular ejection fraction, GDMT e guideline directed medical therapy, NYHA e New York Heart Association, CVD e car-
diovascular disease, MI emyocardial infarction, HF e heart failure, HR e heart rate, min eminute, CrCl e creatinine clearance, AF e atrial fibrillation, NSVT e non-sustained ventricular tachycardia,
MTWA emicrovolt T wave alternans, VA e ventricular arrhythmia, VT e ventricular tachycardia, BMI e body mass index, SBP e systolic blood pressure, LBBB e left bundle branch block.
a Hazard ratio/relative risk ratio not reported.
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Table 2 e Risk stratification tools for prediction of sudden cardiac death in other disease populations.
Ref Study name (location) Population Risk stratification tool Hazard ratio or relative
risk for endpoint (95% CI)
p Value
Non-ischemic cardiomyopathy (NICM)
47 (Slovenia) HF NYHA class III or IV, LVEF <40% (n ¼ 398) QTc increase of 10% after 1 year f/u 5.98 (1.05e24.74) 0.006
26 (U.K) NICM (n ¼ 472) Fibrosis on LGE-CMR 4.61 (2.75e7.74) <0.001
Fibrosis extent on LGE-CMR (per 1% increment) 1.10 (1.05e1.16) <0.001
27 Meta-analysis CAD or NICM (n ¼ 1105) LV scar on LGE-CMR 4.33 (2.98e6.29) NA
25 MUSIC study (Spain) HF NYHA class II or III (n ¼ 650) TWA, index of average alternans>3.7uV 2.29 (1.31e4.00) 0.004
TWA, index of average alternans at HR 90 1.07 (1.00e1.15) 0.046
14 (China) DCM LVEF <45% despite medical therapy,
NYHA IIeIV
J wave in the inferior leads (n ¼ 572) 4.095 (2.132e7.863) <0.001
b1 receptor auto-antibodies (n ¼ 704) 4.514 (2.405e8.471) <0.001
48 ALPHA study (Italy) NICM, LVEF 40%, NYHA class IIeIII (n ¼ 446) TWA 5.53 (1.29e23.65) 0.004
49 (Austria) LVEF<35% (n ¼ 452) log (BNP) Chi square: 11.8125 0.0006
Suspected heart disease
50 (Argentina) Chest pain patients with suspected ACS (n ¼ 982) Vitamin D (Highest quartile vs. lowest quartile) 0.32 (0.11e0.94) 0.038
30 Finnish Cardiovascular Study
(Finland)
Patients getting stress test (n ¼ 1297) TCRT/HR loop area (<2.597 vs. >2.597) 10.7 (1.4e83.7) 0.024
Baseline TCRT (<0 vs. >0) 5.0 (1.1e22.7) 0.038
29 LURIC study (Germany) Patients referred for coronary angiography (n ¼ 3303) Plasma renin concentration (per SD log increase) 1.23 (1.10e1.38) <0.001
28 (U.S.A) Patients in sinus rhythm having EP study (n ¼ 313) TWA 12.2 <0.0001
PVS 3.0 <0.0001
End stage renal disease (ESRD)
35 (Netherlands) Dialysis patients (n ¼ 277) QRS-T angle 130 in men and 116 in women 2.99 (1.04e8.60) NA
34 (Hong Kong) ESRD on PD for3months (n ¼ 230) LVEF (per 1% increase) 0.94 (0.89e0.98) 0.004
SBP (per 1 mmHg increase) 1.05 (1.02e1.08) 0.0031
DBP (per 1 mmHg increase) 0.92 (0.87e0.97) 0.0033
Cardiac troponin T (per 1ug/L increase) 1.14 (1.01e1.31) 0.031
Obstructive sleep apnea (OSA)
32 (U.S.A) Adult having first diagnostic polysomnogram
(n ¼ 10701)
Apnea-hypoapnea index>20 1.60 (1.14e2.24) 0.007
Mean nocturnal SaO2<93% 2.93 (1.98e4.33) <0.0001
Lowest nocturnal SaO2<78% 2.60 (1.85e3.65) <0.0001
Age >60 years 5.53 (3.84e7.94) <0.0001
Other
51 SEAS study (USA, Europe) Mild-moderate AS, age 45e85 (n ¼ 1542) QRS duration (<85 ms vs.>100 ms without BBB) 5.0 (1.8e13.7) 0.002
52 LIFE study (USA, Scandinavia) HTN, LVH on ECG, sinus rhythm (n ¼ 8831) New onset AF 3.13 (1.87e5.24) <0.001
53 (UK) SVT or NSVT (n ¼ 373) Fibrosis on LGE-CMR 3.3 (1.8e5.8) <0.001
NYHA e New York Heart Association, LGE-CMR e late gadolinium enhancement cardiac magnetic resonance imaging, CAD e coronary artery disease, LV e left ventricle, TWA e T wave alternans,
DCM e dilated cardiomyopathy, BNP e brain natriuretic peptide, TCRT e Total cosine R-to-T, ACS e acute coronary syndrome, PVS e programmed ventricular stimulation, ESRD e end-stage renal
disease, PDe peritoneal dialysis, LVEFe left ventricular ejection fraction, S/DBPe systolic/diastolic blood pressure, LVHe left ventricular hypertrophy, AFe atrial fibrillation, (N)SVTe (non-)sustained
ventricular tachycardia.
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nomic parameters on risk of sudden cardiac death, however
the majority of studies on this topic have small sample sizes.
One exception is the ATRAMI study, which evaluated the ef-
fect of heart rate variability and baroreflex sensitivity on the
risk of cardiac arrest.23 Of note, the endpoint of this study
included both arrhythmic and non-arrhythmic causes of
cardiac arrest. The composite of autonomic parameters had a
relative risk of 16.79 (95% CI 6.01 to 46.89, p< 0.0001) of cardiac
arrest.24 Autonomic parameters have so far had limited use in
the clinical setting and need to be studied further to determine
their prognostic value.3. Primary prevention of SCD in patients
with other cardiac and non-cardiac disease
3.1. Patients with non-ischemic cardiomyopathy (NICM)
Current guidelines for ICD use in patients with NICM recom-
mend implantation in patients with LVEF 35%, NYHA class
IeIII heart failure, following goal-directed medical therapy
(GDMT) for a minimum of 3 months. ICD use is also recom-
mended in patients with specific cardiomyopathy types: those
patients with LVEF 35% and sarcoid heart disease, myotonic
dystrophy, Chagas disease, or persistent peripartum cardio-
myopathy. In addition, ICD use is recommended in patients
with Giant cell myocarditis, regardless of LVEF.9 New tech-
nologies available for quantitative characterization of T-wave
alternans (TWA), and examination for structural heart disease
using cardiac MRI have now been shown to have statistically
significant predictive value in determining SCD risk (see
Table 2).
TheMuerte Su´bita en Insuficiencia Cardiaca (MUSIC) study,
published in 2011 assessed the prognostic value of TWA
amongst NYHA class II and III heart failure patients, without
specifying the etiology of the heart failure. Using a fully auto-
mated system for themeasurement of TWA,with quantitative
measures of the degree of alternans, this study showed an
increased risk of SCD (HR ¼ 2.29) in patients with a higher de-
gree of TWA after a median follow up period of 48 months.25
Quantification of myocardial scar burden using late gado-
linium enhancement cardiac magnetic resonance imaging
(LGE-CMR) has also been shown to be associated with SCD
risk. A 2013 study by Gulati et al found that both myocardial
fibrosis, and increased fibrosis extent were independently
associated with SCD in patients with NICM.26 A 2013 meta-
analysis by Scott et al comprising a total of 1105 patients
also found an increased risk of SCD with greater extent of left
ventricular scar burden.27
3.2. Patients with suspected cardiovascular disease
There have been several studies evaluating SCD risk in pa-
tients with suspected cardiovascular disease, with cohorts of
patients being recruited from referrals for various cardiovas-
cular testing modalities (see Table 2).
In a study published by Gold et al in 2000, 313 patients
referred for electrophysiologic study were evaluated by TWA
and signal averaged ECG, then followed up for 400 days. Onmultivariate analysis, they found that only TWA and EPS were
independent predictors of SCD. Of note, the cohort of patients
with TWA had an LVEF which was lower than those patients
without TWA (35  17% vs. 54  13%, p ¼ 0.001).28
In Germany, the Ludwigshafen Risk and Cardiovascular
Health (LURIC) Study enrolled a cohort of 3303 patients
referred for coronary angiography. Here, an increased plasma
renin concentration, a marker of activation of the
renineangiotensinealdosterone axis, weakly correlated with
increased risk of SCD at a median follow up of 9.9 years (HR
1.23, p < 0.001).29
Subsequently, the Finnish Cardiovascular study evaluated
ECG parameters in patients referred for bicycle stress test.
They found that attenuated hysteresis of the depolarization
and repolarization wave fronts (total cosine R-to-T, TCRT)
during the recovery period after exercise were predictive of
SCD after a mean follow up period of 45 months (HR 10.7,
p ¼ 0.024).30
3.3. Patients with obstructive sleep apnea
There is a known association between obstructive sleep apnea
and sudden cardiac death. Putative mechanisms proposed to
explain these associations include intermittent hypoxia and
recurrent arousals, leading to sympathetic activation and
electrical and structural remodeling of the heart, predisposing
to cardiac arrhythmias.31 A 2013 study by Gami et al evaluated
the SCD risk at an average of 5.3 years of follow up in adults
undergoing their first diagnostic polysomnogram. SCD was
found to be best predicted by age>60 years, apnea-hypoapnea
index >20, mean nocturnal oxygen saturation <93%, and
lowest nocturnal oxygen saturation <78%.32 In OSA patients,
adherence to use of continuous positive airway pressure
ventilation during sleep has been shown to decrease adverse
cardiac events.31
3.4. Patients with end-stage renal disease (ESRD)
The risk of cardiovascularmortality in ESRD patients is known
to be 10e100 fold higher than age, sex, and race matched
controls in the general population. In particular, SCD accounts
for 26.1% of deaths in the ESRD population, and these deaths
do not appear to be caused by coronary artery disease.33 A
2010 study byWang et al found that amongst ESRD patients on
peritoneal dialysis for over 3 months, after a 5 year follow up,
higher LVEF and diastolic blood pressure were associated with
a decreased risk of SCD whereas increased systolic blood
pressure was associated with an increased risk of SCD.34 A
recent study from the Netherlands on chronic dialysis pa-
tients showed that abnormal QRS-T spatial angle on surface
ECG was predictive of SCD and all cause mortality.35
Currently, there is no consensus on the true survival benefit
derived from ICD implantation in patients with ESRD.4. Primary prevention of SCD in the general
population
As the absolute number of SCD events which occur in the
general population outnumber those which occur in high risk
Table 3 e Risk stratification tools for prediction of sudden cardiac death in the general population, listed in order of increasing hazard ratios.
Ref Study name Population Risk stratification tool HR or RR for SCD (95%CI) p value
54 Kuopio (Finland) Men 42e60 (n ¼ 2368) Cardiorespiratory fitness (per 1 MET increase) 0.78 (0.71e0.84) <0.001
55 CHS (U.S.A) Adults 65 (n ¼ 3089) Highly sensitive troponin T (1 pg/ml per year
increase from baseline)
1.03 (1.01e1.06) 0.03
56 WHI (U.S.A) Women (n ¼ 161,808) Older age 1.09 (1.07e1.11) NA
57 CHS (U.S.A) Adults 65 (n ¼ 5806) CRP (þ1 log increase) 1.13 (1.00e1.28) 0.049
58 ARIC study (U.S.A) Adults 45e64 (n ¼ 14,574) APCs on 2 min telemetry strip 1.15 (0.56e2.39) NA
59 Kuopio (Finland) Men 42e61 (n ¼ 2666) SBP at rest (per 10 mmHg increment) 1.15 (1.07e1.25) <0.001
60 Health 2000 (Finland) Adults 30 (n ¼ 5618) T-wave residuum (per SD increment) 1.2 (1.0e1.5) 0.05
55 CHS (U.S.A) Adults 65 (n ¼ 4431) Highly sensitive troponin T (þ1 log increase) 1.26 (1.01e1.57) 0.04
57 CHS (U.S.A) Adults 65 (n ¼ 5382) IL-6 (þ1 log increase) 1.26 (1.02e1.56) 0.04
61 Kuopio (Finland) Men 42e60 (n ¼ 2049) QRS duration (per 10 ms increase) 1.27 (1.14e1.40) <0.001
60 Health 2000 (Finland) Adults 30 (n ¼ 5618) Total cosine R-to-T (per SD decrement) 1.3 (1.1e1.6) 0.013
60 Health 2000 (Finland) Adults 30 (n ¼ 5618) T-wave morphology dispersion (per SD increment) 1.4 (1.1e1.7) 0.001
56 WHI (U.S.A) Women (n ¼ 161,808) History of hypertension 1.46 (1.11e1.93) NA
62 Kuopio (Finland) Men 42e60 (n ¼ 2641) Impaired fasting glucose 1.51 (1.07e2.14) 0.02
56 WHI (U.S.A) Women (n ¼ 161,808) Race (AfricaneAmerican vs. White) 1.61 (1.18e2.19) NA
WHI (U.S.A) Women (n ¼ 161,808) History of carotid artery disease 1.72 (1.03e2.87) NA
WHI (U.S.A) Women (n ¼ 161,808) Waist:hip (Highest vs. lowest quartile) 1.73 (1.20e2.48) NA
WHI (U.S.A) Women (n ¼ 161,808) History of DM 2.00 (1.55e2.58) NA
58 ARIC study (U.S.A) Adults 45e64 (n ¼ 14,574) VPCs on 2 min telemetry strip 2.09 (1.22e3.56) NA
63 CHD study (Finland) Adults 30e59 (n ¼ 10,957) T wave axis (10 or100 vs. 0e90) 2.13 (1.63e2.79) <0.001
64 CHS (U.S.A) Adults 65 (n ¼ 2312) Vitamin D and PTH (<20, 65 vs. 20, <65) 2.16 (1.15e4.05) NA
63 CHD study (Finland) Adults 30e59 (n ¼ 10,957) QRST angle (>100 vs. < 100) 2.26 (1.59e3.21) <0.001
56 WHI (U.S.A) Women (n ¼ 161,808) Current smoker 2.26 (1.66e3.09) NA
65 Nurses Health Study (USA) Female nurses 30e55 (n ¼ 121,701) Current smoker 2.44 (1.80e3.31) NA
66 Meta-analysis Meta-analysis (n ¼ 106,195) VPCs >1 on ECG or >30 on 1 h telemetry 2.64 (1.93e3.63) NA
67 CHS (U.S.A) Adults 65 (n ¼ 4465) Cystatin C (1.10 mg/L vs. 0.91 mg/L) 2.67 (1.33e5.35) NA
CHS (U.S.A) Adults 65 (n ¼ 4465) Cystatin C (0.92 mg/L to 1.09 mg/L vs. 0.91 mg/L) 2.72 (1.44e5.16) NA
68 Physician’s Health
Study (U.S.A)
Male physicians 40e84 (n ¼ 22,071) CRP (Highest quartile vs. lowest quartile) 2.78 (1.35e5.72) <0.001
62 Kuopio (Finland) Men 42e60 (n ¼ 2641) History of DM 2.86 (1.87e4.38) <0.001
58 ARIC study (U.S.A) Adults 45e64 (n ¼ 14,574) APCs and VPCs on 2 min telemetry 6.39 (2.58e15.84) NA
CRP e C-reactive protein, A/VPC e atrial/ventricular premature complex, SBP e systolic blood pressure, SD e standard deviation, DM e diabetes mellitus, PTH e parathyroid hormone, NA e not
available.
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i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 7 1es 8 1S78groups,1 a review of risk stratification for SCD would be
incomplete without addressing the general population. There
are no official recommendations for prophylactic ICD use for
primary prevention of SCD in this group with good reason; the
incidence rate is so low that any attempt at mitigating risk
with ICD use would by far be overshadowed by the inherent
risks of ICD use in large number of those who will never
experience a fatal arrhythmic event.
Nevertheless, in recent years, there have been several long
term prospective studies in large cohorts of the general pop-
ulation, evaluating the predictive power of various clinical
tools for SCD, summarized in Table 3. These studies all eval-
uate various baseline characteristics, and followed patient
outcomes over an average time span of between 7.7 and 30
years. Interestingly, almost all of these studies originated
from patient populations in the United States and Finland.
The applicability of this data to other parts of the world re-
mains unclear.5. A brief word on secondary prevention ICD
use
Secondary prevention ICD use has been found to have a
mortality benefit over anti-arrhythmic therapy in multiple
clinical trials, and requires fewer numbers of patients to be
treated per life saved compared to primary prevention pop-
ulations.36e38 Current guidelines recommend ICD use in pa-
tients with resuscitated cardiac arrest due to VT/VF which
does not have a reversible cause. It is also indicated in patients
following cardiac arrest due to MI who are not candidates for
complete revascularization. Patients with syncope of unde-
termined origin, who have inducible VT/VF on EPS are also
candidates for ICD therapy.396. Conclusions
The oldest and most reproducible evidence for predictors of
SCD comprise the current guidelines for ICD use. We have
reviewed here the evidence that has been accrued beyond
what is reflected in the guidelines, and which will likely in-
crease the predictive power for SCD events. All studies involve
a one-time evaluation of a certain parameter, so the risk es-
timate applies to the length of the follow up period for each
study. In studies of patients with IHD, the follow up duration
has been as short as one year, and in studies of the general
population, up to 30 years. In the future, an important area of
study will be to identify those patients at imminent risk of
death in the days or weeks following their presentation to
medical attention who may require sooner intervention with
ICD or with bridging strategies to ICD, such as wearable car-
dioverter defibrillators.40
While ICDs have clearly been shown to reduce the risk of
SCD, they do not eliminate this risk. The SCD-HeFT trial
showed that the deaths due to SCD in the group treated with
ICD vs. placebo was 20% vs. 39%.41 This observation is specific
to the trial population of patients with LVEF 35% and NYHA
class IIeIII heart failure, so other populations of patients may
derive different levels of benefit from ICD therapy.Furthermore, ICD’s carry the risks of implant-related compli-
cations including infection, lead-related malfunction, and
inappropriate shocks; some of these complications may be
mitigated by recent technologic advancements such as the
subcutaneous ICD. For that reason, the studies reviewed here
may also help the astute clinician to identify a low risk cohort
amongst those patients with ICD indications, in whom, a
combination of patient preference and individual risk due to
comorbidities may negate the potential benefit of ICD.
The tools reviewed here carry a range of cost, equipment,
time, and personnel requirements. The least expensive tools
are factors from a patient’s medical history (personal and
family), followed by blood pressure and heart rate measure-
ments, then elements of the surface ECGwhich can be read by
a practitioner without analysis by specialized software. Bio-
markers have variable costs depending on complexity of the
assay. Imaging and EPS require the equipment, technicians,
and qualified interpreters of the results. For this reason,
developing a risk stratification scheme will depend heavily
upon the resources available to the medical system, the
clinician and the patient, and ultimately must be a case by
case interpretation of both published guidelines and the
additional data presented here.Conflicts of interest
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